Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Zeria Pharmaceutical applies for approval of Z-213 in Japan

March 29, 2018

Edge Therapeutics discontinues phase III NEWTON 2 study of EG-1962

March 29, 2018

European Commission expands indication for Feraccru

March 28, 2018

Jiangsu Hengrui Medicine Co., Shanghai Hengrui Pharmaceutical Co. patent factor XIa inhibitors

March 27, 2018

Hemlibra approved in Japan

March 27, 2018

EMA committee issues negative opinion on Portola's betrixaban

March 26, 2018

First patient dosed in phase III study of BCX-7353 for HAE

March 16, 2018

Positive topline data from phase III study of ALXN-1210 in patients with PNH

March 16, 2018

Interim ANNEXA-4 data show high rate of hemostasis with andexanet alfa

March 15, 2018

Merck & Co. discovers FXIa and plasma kallikrein inhibitors

March 13, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...